UCBJF News Alert Ucb S A (UCBJF) 80.2600 12/25/2014 07:05:00

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ucb S A (UCBJF) 80.2600 $UCBJF

UCB's Kremers Urban Sale Deal Lapses, Divestiture Plan On - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 2:20PM CST
UCB (UCBJF), Advent International and Avista Capital Partners announced their decision to mutually terminate their deal for the acquisition of UCB's Kremers Urban.
LCI: 42.29 (+1.79), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44)

UCB Reports Phase III Data on Epilepsy Drug, To File in 2015 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 1:50PM CST
UCB SA (UCBJF) announced positive primary efficacy and safety data from its latest phase III study on its epilepsy candidate, brivaracetam.
LCI: 42.29 (+1.79), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44)

UCB-Daiichi Sankyo Ink Deal to Sell Vimpat in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 2:20PM CST
UCB SA (UCBJF) and Daiichi Sankyo have signed a deal to jointly commercialize Vimpat for the treatment of epilepsy in Japan.
IPXL: 31.32 (+0.26), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44)

Immunomedics' Veltuzumab Receives Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 3:20PM CST
Immunomedics' (IMMU) anti-CD20 antibody, veltuzumab, was granted an orphan drug status in the U.S. for the treatment of pemphigus.
BIIB: 340.89 (+5.13), IMMU: 4.41 (+0.13)

Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 254.20 (-1.68), QLTI: 3.72 (+0.08), VRX: 140.33 (-0.22), AGN: 210.12 (+0.95), SHPG: 209.29 (+0.07), AUXL: 34.40 (+0.18), ABBV: 66.21 (+1.86), SNY: 46.35 (+0.50), ABT: 45.70 (-0.02), ENDP: 72.10 (+0.34), AKRX: 36.47 (+0.43), PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), SLXP: 114.92 (-1.18), MYL: 56.97 (+0.39), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), ACHN: 13.06 (+1.22), MRK: 57.46 (+0.25), AZN: 70.44 (+0.26), ICPT: 151.49 (+5.85), TEVA: 57.09 (+0.33), NVS: 93.91 (+0.66)

Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 254.20 (-1.68), QLTI: 3.72 (+0.08), VRX: 140.33 (-0.22), AGN: 210.12 (+0.95), SHPG: 209.29 (+0.07), AUXL: 34.40 (+0.18), ABBV: 66.21 (+1.86), SNY: 46.35 (+0.50), ABT: 45.70 (-0.02), ENDP: 72.10 (+0.34), AKRX: 36.47 (+0.43), PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), SLXP: 114.92 (-1.18), MYL: 56.97 (+0.39), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), ACHN: 13.06 (+1.22), MRK: 57.46 (+0.25), AZN: 70.44 (+0.26), ICPT: 151.49 (+5.85), TEVA: 57.09 (+0.33), NVS: 93.91 (+0.66)

Will Catalyst Pharmaceuticals' (CPRX) Loss Narrow in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:30PM CST
Catalyst Pharmaceuticals Inc, Inc. (CPRX) is expected to report third-quarter 2014 results on Nov 13.
MNK: 97.84 (-0.29), BMRN: 88.18 (+0.89), CPRX: 2.90 (-0.02)

UCB to Sell Generics Business, Focus on Core Segments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:30PM CST
UCB SA (UCBJF) entered into an agreement with Advent International and Avista Capital Partners for the sale of its specialty generics subsidiary for $1.525 billion.
LCI: 42.29 (+1.79), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), NVS: 93.91 (+0.66)

UCB jettisons U.S. generic business
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:20AM CST


UCB-Amgen Reveals Positive Data on Romosozumab for PMO - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 5:40PM CDT
UCB SA (UCBJF) and Amgen announced positive results from exploratory analyses of a phase II study on romosozumab in postmenopausal women with low bone mineral density.
GILD: 91.29 (+1.84), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42)

Roche's (RHHBY) RoActemra Gets EU Approval for Early RA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 4:20PM CDT
Positive news flowed in at Roche (RHHBY) when its RA drug RoActemra received approval from the European Commission to treat patients suffering from early RA who have previously not been treated with methotrexate (MTX).
AGN: 210.12 (+0.95), ABBV: 66.21 (+1.86)

UCB's Epilepsy Drug Vimpat's Label Expanded in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 3:45PM CDT
UCB's (UCBJF) Vimpat has been approved in the U.S. as monotherapy for the treatment of partial-onset seizures in epilepsy patients aged 17 years and above.
AGN: 210.12 (+0.95), LCI: 42.29 (+1.79), ENDP: 72.10 (+0.34)

UCB Files Patent Infringement Lawsuit vs. Actavis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:40PM CDT
Actavis has filed an ANDA with the FDA seeking marketing approval for its generic version of UCB's Neupro. In response, UCB filed a lawsuit against Actavis.
MNK: 97.84 (-0.29), ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43)

Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), RIGL: 2.22 (+0.02), NVO: 43.80 (+1.08), MRK: 57.46 (+0.25), AZN: 70.44 (+0.26), ABBV: 66.21 (+1.86), NVS: 93.91 (+0.66), CELGZ: 3.34 (-0.01)

UCB's Brivaracetam Positive in Phase III Epilepsy Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 4:40PM CDT
UCB SA (UCBJF) announced positive top-line results from a phase III study on epilepsy candidate, brivaracetam.
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), GSK: 42.85 (+0.11)

UCB, Dermira Sign Cimzia Dermatology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 5:10PM CDT
UCB SA (UCBJF) and Dermira have entered into a licensing agreement for the development and commercialization of Cimzia in dermatology.
BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), ARIA: 6.81 (+0.15)

UCB's Vimpat Positive for Partial-Onset Seizures - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 10:50AM CDT
UCB SA (UCBJF) announced positive data from two studies on Vimpat as an early adjunctive therapy in adults suffering from partial-onset seizures.
BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), ARIA: 6.81 (+0.15)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 107

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 75

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
Niron's $1.8B Alabama Bet Carries Big Magnet Stakes

Updated Category News Views 54

A Huge Factory Claim Needs More Than Applause A magnet company just tossed a very large number onto Alabama's economic-development table. Niron Magnetics says it plans a $1.8 billion investment in the state that would create 700 jobs. That is not pocket change, not a ribbon-cutting trinket, and not the sort of announcement investors should breeze past between earnings...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 138

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 53

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 167

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 70

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 119

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 57

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Microinsurance Market Expected to Surpass $11 Billion by 2034

Updated Category News Views 137

Growth Trajectory of the Global Microinsurance Market The microinsurance market is witnessing remarkable transformation as consumer demands shift towards financial inclusion, coupled with increasing awareness of the myriad advantages insurance provides. This positive trend is fueled by government initiatives aimed at regulation and expansion of microinsurance offerings,...

Continue Reading
Ormat Technologies Launches Secondary Stock Offering

Updated Category News Views 188

Ormat Technologies Launches Secondary Stock Offering Ormat Technologies, Inc. (NYSE: ORA), renowned for its innovative geothermal and renewable energy solutions, recently announced an exciting development in the investment realm—the initiation of an underwritten secondary offering. This offering encompasses a total of 3,700,000 shares of common stock on behalf of ORIX...

Continue Reading
MongoDB Executive Share Transactions Highlight Growth Potential

Updated Category News Views 132

Insights from MongoDB Executive Share Transactions Cochran Hope F, a director at MongoDB, Inc. (NASDAQ: MDB), recently made notable moves with the company's Class A Common Stock, and these transactions were disclosed in the latest SEC filings. This activity has attracted attention from investors. In September, the director sold 1,174 shares at $224.38 each, which brought...

Continue Reading
Essential Guidance for Navigating Hurricane Travel Risks

Updated Category News Views 69

Essential Guidance for Navigating Hurricane Travel Risks Hurricane season brings with it the potential for severe weather that can disrupt travel plans and lead to significant financial losses. As storms like Hurricane Helene have shown, the impact can be widespread, devastating homes and infrastructure, particularly in the southeastern regions. During these turbulent...

Continue Reading
Ascend Performance Materials Launches High-Purity Production

Updated Category News Views 279

Ascend Performance Materials Starts High-Purity Acrylonitrile Production Ascend Performance Materials has recently announced an exciting new phase in its production capabilities. The company is now producing high-purity acrylonitrile at its Chocolate Bayou facility. This advancement comes after the successful installation and commissioning of state-of-the-art purification...

Continue Reading